Cargando…

Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy

OBJECTIVES: The objective of this study was to determine the incidence of retinopathy in chronic hepatitis C patients treated with Pegylated interferon alpha 2a and Ribavirin. METHODS: This descriptive case series study was conducted in Medical Unit II of the Jinnah Hospital Lahore from September 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashif, Muhammad, Saleem, Muhammad Khurram, Farooka, Imran Khan, Husnain, Amina, Siddiqui, Arif Mahmood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publicaitons 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386181/
https://www.ncbi.nlm.nih.gov/pubmed/25878638
http://dx.doi.org/10.12669/pjms.311.6321
_version_ 1782365157540757504
author Kashif, Muhammad
Saleem, Muhammad Khurram
Farooka, Imran Khan
Husnain, Amina
Siddiqui, Arif Mahmood
author_facet Kashif, Muhammad
Saleem, Muhammad Khurram
Farooka, Imran Khan
Husnain, Amina
Siddiqui, Arif Mahmood
author_sort Kashif, Muhammad
collection PubMed
description OBJECTIVES: The objective of this study was to determine the incidence of retinopathy in chronic hepatitis C patients treated with Pegylated interferon alpha 2a and Ribavirin. METHODS: This descriptive case series study was conducted in Medical Unit II of the Jinnah Hospital Lahore from September 2012 to February 2013. One hundred chronic hepatitis C patients visiting Medical Unit II outpatient department fulfilling inclusion criteria were selected for this study via non probability purposive sampling. Patients were started on pegylated interferon and ribavirin combination therapy. Subjects were subjected to dilated eye fundoscopic examination at the start of therapy and then after three months of the therapy. RESULTS: One hundred patients were included in this study. Out of these 100 patients 5% developed retinopathy whereas fundus examination was normal in rest of the patients. CONCLUSION: Interferon therapy can lead to retinopathy. Periodic fundoscopic examinations help in early detection and prevent progression to permanent visual loss.
format Online
Article
Text
id pubmed-4386181
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Professional Medical Publicaitons
record_format MEDLINE/PubMed
spelling pubmed-43861812015-04-15 Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy Kashif, Muhammad Saleem, Muhammad Khurram Farooka, Imran Khan Husnain, Amina Siddiqui, Arif Mahmood Pak J Med Sci Original Article OBJECTIVES: The objective of this study was to determine the incidence of retinopathy in chronic hepatitis C patients treated with Pegylated interferon alpha 2a and Ribavirin. METHODS: This descriptive case series study was conducted in Medical Unit II of the Jinnah Hospital Lahore from September 2012 to February 2013. One hundred chronic hepatitis C patients visiting Medical Unit II outpatient department fulfilling inclusion criteria were selected for this study via non probability purposive sampling. Patients were started on pegylated interferon and ribavirin combination therapy. Subjects were subjected to dilated eye fundoscopic examination at the start of therapy and then after three months of the therapy. RESULTS: One hundred patients were included in this study. Out of these 100 patients 5% developed retinopathy whereas fundus examination was normal in rest of the patients. CONCLUSION: Interferon therapy can lead to retinopathy. Periodic fundoscopic examinations help in early detection and prevent progression to permanent visual loss. Professional Medical Publicaitons 2015 /pmc/articles/PMC4386181/ /pubmed/25878638 http://dx.doi.org/10.12669/pjms.311.6321 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kashif, Muhammad
Saleem, Muhammad Khurram
Farooka, Imran Khan
Husnain, Amina
Siddiqui, Arif Mahmood
Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title_full Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title_fullStr Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title_full_unstemmed Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title_short Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
title_sort incidence of retinopathy in chronic hepatitis c patients treated with pegylated interferon alpha 2a and ribavirin combination therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386181/
https://www.ncbi.nlm.nih.gov/pubmed/25878638
http://dx.doi.org/10.12669/pjms.311.6321
work_keys_str_mv AT kashifmuhammad incidenceofretinopathyinchronichepatitiscpatientstreatedwithpegylatedinterferonalpha2aandribavirincombinationtherapy
AT saleemmuhammadkhurram incidenceofretinopathyinchronichepatitiscpatientstreatedwithpegylatedinterferonalpha2aandribavirincombinationtherapy
AT farookaimrankhan incidenceofretinopathyinchronichepatitiscpatientstreatedwithpegylatedinterferonalpha2aandribavirincombinationtherapy
AT husnainamina incidenceofretinopathyinchronichepatitiscpatientstreatedwithpegylatedinterferonalpha2aandribavirincombinationtherapy
AT siddiquiarifmahmood incidenceofretinopathyinchronichepatitiscpatientstreatedwithpegylatedinterferonalpha2aandribavirincombinationtherapy